These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 8748615

  • 1. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
    Blanchet PJ, Gomez-Mancilla B, Bédard PJ.
    J Neural Transm Suppl; 1995; 45():103-12. PubMed ID: 8748615
    [Abstract] [Full Text] [Related]

  • 2. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N, Mizuta E, Yoshida O, Kuno S.
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [Abstract] [Full Text] [Related]

  • 4. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 5. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

  • 6. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
    Blanchet PJ, Calon F, Martel JC, Bédard PJ, Di Paolo T, Walters RR, Piercey MF.
    J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
    [Abstract] [Full Text] [Related]

  • 7. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P, Bédard PJ, Britton DR, Kebabian JW.
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [Abstract] [Full Text] [Related]

  • 8. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T.
    Adv Neurol; 1993 Oct; 60():113-8. PubMed ID: 8093573
    [No Abstract] [Full Text] [Related]

  • 9. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 10. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists.
    Khroyan TV, Barrett-Larimore RL, Rowlett JK, Spealman RD.
    J Pharmacol Exp Ther; 2000 Aug; 294(2):680-7. PubMed ID: 10900248
    [Abstract] [Full Text] [Related]

  • 11. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 12. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Gomez-Mancilla B, Bédard PJ.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
    [Abstract] [Full Text] [Related]

  • 13. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ, Grondin R, Bédard PJ.
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [Abstract] [Full Text] [Related]

  • 14. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 15. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M.
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [Abstract] [Full Text] [Related]

  • 16. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M, Madras BK.
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [Abstract] [Full Text] [Related]

  • 17. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [Abstract] [Full Text] [Related]

  • 18. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P.
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [Abstract] [Full Text] [Related]

  • 19. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias.
    Robertson HA.
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):147-52. PubMed ID: 1349263
    [Abstract] [Full Text] [Related]

  • 20. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.